Roghanian Ali, Stopforth Richard J, Dahal Lekh N, Cragg Mark S
Antibody and Vaccine Group, Centre for Cancer Immunology, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
J Leukoc Biol. 2018 Feb 6. doi: 10.1002/JLB.2MIR0917-354R.
The Fc gamma receptor IIB (FcγRIIB/CD32B) was generated million years ago during evolution. It is the sole inhibitory receptor for IgG, and has long been associated with the regulation of humoral immunity and innate immune homeostasis. However, new and surprising functions of FcγRIIB are emerging. In particular, FcγRIIB has been shown to perform unexpected activatory roles in both immune-signaling and monoclonal antibody (mAb) immunotherapy. Furthermore, although ITIM signaling is an integral part of FcγRIIB regulatory activity, it is now clear that inhibition/activation of immune responses can occur independently of the ITIM. In light of these new findings, we present an overview of the established and noncanonical functions of FcγRIIB and discuss how this knowledge might be exploited therapeutically.
Fcγ受体IIB(FcγRIIB/CD32B)在数百万年前的进化过程中产生。它是IgG的唯一抑制性受体,长期以来一直与体液免疫调节和固有免疫稳态相关。然而,FcγRIIB新的、令人惊讶的功能正在不断涌现。特别是,FcγRIIB已被证明在免疫信号传导和单克隆抗体(mAb)免疫治疗中发挥意想不到的激活作用。此外,虽然免疫受体酪氨酸抑制基序(ITIM)信号传导是FcγRIIB调节活性的一个组成部分,但现在很清楚,免疫反应的抑制/激活可以独立于ITIM发生。鉴于这些新发现,我们概述了FcγRIIB已确定的和非经典的功能,并讨论了如何在治疗中利用这些知识。